Oppenheimer analyst Jay Olson maintains $Intellia Therapeutics (NTLA.US)$ with a buy rating, and maintains the target price at $70.
According to TipRanks data, the analyst has a success rate of 38.6% and a total average return of 12.4% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Intellia Therapeutics (NTLA.US)$'s main analysts recently are as follows:
The assessment of Intellia Therapeutics' NTLA-2002 Phase 2 data indicated a reduction in attacks, which, while comparable to competitors' Phase 3 trials, was perceived as less impressive compared to the company's Phase 1 outcomes for HAE reported in June. Despite this, analysts still consider the 'one-and-done' treatment approach of NTLA-2002 as a significant differentiator from competitors' treatment frequencies, which range from daily to monthly. The market opportunity for NTLA-2002 remains attractive, though there has been a moderation in the expected peak market share and a more cautious perspective on the success probabilities for NTLA-2001 in ATTR, citing the need for further platform derisking.
The firm has revised its stance slightly more negatively after assessing the Phase 2 study results of NTLA-2002 in patients with hereditary angiodema (HAE).
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
